ADAP vs. SRRK, TARS, VIR, AUTL, FDMT, BCRX, IMTX, KYTX, RGNX, and ADMA
Should you be buying Adaptimmune Therapeutics stock or one of its competitors? The main competitors of Adaptimmune Therapeutics include Scholar Rock (SRRK), Tarsus Pharmaceuticals (TARS), Vir Biotechnology (VIR), Autolus Therapeutics (AUTL), 4D Molecular Therapeutics (FDMT), BioCryst Pharmaceuticals (BCRX), Immatics (IMTX), Kyverna Therapeutics (KYTX), REGENXBIO (RGNX), and ADMA Biologics (ADMA). These companies are all part of the "biological products, except diagnostic" industry.
Scholar Rock (NASDAQ:SRRK) and Adaptimmune Therapeutics (NASDAQ:ADAP) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, valuation, media sentiment, analyst recommendations, earnings, institutional ownership, community ranking and profitability.
91.1% of Scholar Rock shares are held by institutional investors. Comparatively, 31.4% of Adaptimmune Therapeutics shares are held by institutional investors. 26.2% of Scholar Rock shares are held by insiders. Comparatively, 12.4% of Adaptimmune Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Scholar Rock presently has a consensus price target of $25.17, suggesting a potential upside of 73.20%. Adaptimmune Therapeutics has a consensus price target of $2.50, suggesting a potential upside of 132.56%. Given Scholar Rock's higher probable upside, analysts clearly believe Adaptimmune Therapeutics is more favorable than Scholar Rock.
Scholar Rock has a beta of 0.9, suggesting that its stock price is 10% less volatile than the S&P 500. Comparatively, Adaptimmune Therapeutics has a beta of 2.39, suggesting that its stock price is 139% more volatile than the S&P 500.
In the previous week, Adaptimmune Therapeutics had 4 more articles in the media than Scholar Rock. MarketBeat recorded 7 mentions for Adaptimmune Therapeutics and 3 mentions for Scholar Rock. Adaptimmune Therapeutics' average media sentiment score of 1.36 beat Scholar Rock's score of 0.18 indicating that Scholar Rock is being referred to more favorably in the media.
Adaptimmune Therapeutics received 161 more outperform votes than Scholar Rock when rated by MarketBeat users. However, 62.93% of users gave Scholar Rock an outperform vote while only 62.53% of users gave Adaptimmune Therapeutics an outperform vote.
Adaptimmune Therapeutics has higher revenue and earnings than Scholar Rock. Scholar Rock is trading at a lower price-to-earnings ratio than Adaptimmune Therapeutics, indicating that it is currently the more affordable of the two stocks.
Scholar Rock has a net margin of 0.00% compared to Scholar Rock's net margin of -188.90%. Adaptimmune Therapeutics' return on equity of -80.48% beat Scholar Rock's return on equity.
Summary
Scholar Rock beats Adaptimmune Therapeutics on 10 of the 19 factors compared between the two stocks.
Get Adaptimmune Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ADAP and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ADAP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Adaptimmune Therapeutics Competitors List
Related Companies and Tools
